# Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)

> **NCT00122538** · PHASE2 · COMPLETED · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 52 (actual)

## Conditions studied

- HIV Infections
- AIDS

## Interventions

- **DRUG:** Efavirenz (EFV)
- **DRUG:** Lamivudine (3TC)
- **DRUG:** Didanosine (ddI)

## Key facts

- **NCT ID:** NCT00122538
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-11
- **Final completion:** 2009-05
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2011-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122538, "Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00122538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*